Biotron Limited
A.B.N. 60 086 399 144

Level 8, 261 George Street
Sydney NSW 2000
Tel: (61-2) 9247 8212
Fax: (61-2) 9247 3932
E-mail: pnightingale@biotron.com.au
Website: www.biotron.com.au

26 February 2007

The Manager - Companies
Australian Stock Exchange Limited
20 Bridge Street
SYDNEY NSW 2000 (18 pages by email)

Dear Madam,

HALF YEAR REPORTS

In accordance with Listing Rule 4.2A, I attach the Company's Appendix 4D and Interim Financial Report for the half year ended 31 December 2006.

Yours sincerely



Peter J. Nightingale
Company Secretary

pjn3677

Appendix 4D

Half Year Report

Name of entity

BIOTRON LIMITED

ABN or equivalent company reference	Financial year ended ('current period')
60 086 399 144	**31 DECEMBER 2006**

Results for announcement to the market

Revenues from ordinary activities	Up	23%	to	497,420
Loss from ordinary activities after tax attributable to members	Up	96%	to	1,741,368
Net loss for the period attributable to members	Up	96%	to	1,741,368

Dividends (distributions)	Amount per security	Franked amount per security
Final dividend Interim dividend	Nil¢ Nil¢	Nil¢ Nil¢
Previous corresponding period Final dividend Interim dividend	Nil¢ Nil¢	Nil¢ Nil¢

Record date for determining entitlements to the dividend. N/A

Brief explanation of any of the figures reported above and short details of any bonus or cash issue or other item(s) of importance not previously released to the market:

The results reflect a continuation of the Company's research and development activities and the Company's policy of expensing research and development expenditure as set out in the Statement of Significant Accounting Policies.

NTA backing	Current period	Previous corresponding period
Net tangible asset backing per ordinary security	3.2 cents	2.2 cents

BIOTRON LIMITED

A.B.N. 60 086 399 144

INTERIM FINANCIAL REPORT
FOR THE HALF YEAR ENDED
31 DECEMBER 2006

BIOTRON LIMITED

CONTENTS

BIOTRON LIMITED

DIRECTORS' REPORT

Your Directors have pleasure in submitting their report together with the interim financial report of Biotron Limited ('the Company') for the half year ended 31 December 2006 and the review report thereon.

Directors

The names of the Directors of the Company in office during or since the end of the half year are:

Mr Michael J. Hoy
Independent and Non-Executive Chairman

Mr Hoy has more than 30 years' corporate experience in Australia, the United Kingdom, USA and Asia. He is Chairman of CityPrint Holdings Pty Limited, a director of Eiffel Technologies Limited and a former director of John Fairfax Holdings Limited and FXF Trust.

He has been a director since 7 February 2000 and Chairman since 16 March 2000.

Dr Michelle Miller, BSc, MSc, PhD, GCertAppFin (Finsia)
Managing Director

Dr Miller has over 20 years' experience in the bioscience industry, with extensive experience in managing commercial bioscience research. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes a number of years at Johnson and Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has experience in early-stage start-ups from time spent as Investment Manager with a specialist bioscience venture capital fund.

She was appointed as Managing Director on 21 June 2002.

Dr Michael S. Hirshorn, MBA, MB, BS
Independent and Non-Executive Director

Dr Hirshorn has over 20 years' experience in the commercialisation of Australian Technology, particularly in the medical device industry, and extensive experience in collaboration with Australian research institutes.

He played a major role in all commercial aspects of Cochlear Limited's development, was a founding director of Resmed Inc., and Chief Executive Marketing for Polartechnics Limited.

He has served on numerous government advisory committees, including the Start IT and T Committee, the Start Grants Biological Sciences Committee of the Department of Industry, Science and Resources, and is currently an Investment Manager with a venture capital firm, Nanyang Ventures.

Dr Hirshorn was appointed as a director on 16 March 2000.

Mr Bruce Hundertmark
Independent and Non-Executive Director

Mr Hundertmark is an independent businessman and company director with a wide range of experience in high technology based company start-up operations and promoting the formation of venture capital companies, including News Datacom Limited in Israel and PT Indo Bio Products in Indonesia.

He is a director of Eiffel Technologies Limited and has been a director of News International PLC, Prudential Cornhill Insurance Limited and was Managing Director of IMFC Limited, a merchant bank.

Mr Hundertmark was appointed as a director on 16 March 2000.

Mr Peter G. Scott
Non-Executive Director

Mr Scott is a founding director of Biotron Limited with more than 30 years of commercial and entrepreneurial experience in Australia.

He is a director of Scott's Acorn Pty Ltd, and was formerly Chairman and Managing Director of Scottcom Pty Ltd and Managing Director of ICAM Pty Ltd and other audio visual and multimedia companies.

Mr Scott has been a director since 23 February 1999.

Peter J. Nightingale
Company Secretary

Mr Nightingale graduated with a Bachelor of Economics degree from the University of Sydney and is a member of the Institute of Chartered Accountants in Australia. He has worked as a chartered accountant in both Australia and the USA.

As a director or company secretary Mr Nightingale has, for the past 20 years, been responsible for the financial control, administration, secretarial and in-house legal functions of a number of private and public listed companies in Australia, the USA and Europe including Pangea Resources Limited, Timberline Minerals Inc., Perseverance Corporation Limited, Valdora Minerals N.L. and ETT Limited. Mr Nightingale is currently a director or company secretary of Bolnisi Gold NL, Cockatoo Coal Limited, IMD Group Limited, Planet Gas Limited and Palmarejo Silver and Gold Corporation.

Review of Operations

The period under review has seen a major focus on Biotron's antiviral drug development program, with a particular emphasis on clinical development of its anti-HIV therapeutic candidate BIT225.

Significant events achieved in this half year period include:

- Manufacture and supply of kilo-scale quantities of BIT225, manufactured to GMP-grade.
- Completion of formal preclinical safety program for BIT225.
- Submissions made seeking regulatory and ethics approvals for the commencement of anti-HIV human trials.
- Demonstration of activity of Biotron compounds, including BIT225, in surrogate models of hepatitis C virus (HCV) infection.
- Presentation of preclinical efficacy of compounds against HCV at international HCV meeting.
- Presentation of preclinical efficacy of BIT225 against HIV at international HIV meeting in Cancun, Mexico.
- Agreement with the Australian National University (ANU) generated significant benefit to the Company in the form of $442,703 cash and transfer of ownership of key Virion patents.

Virion

Biotron's Virion project has reached a number of key milestones during this half year period. The first occurred in July 2006, when Biotron received shipment of kilo-scale quantities of BIT225, the Company's lead anti-HIV drug. This material was manufactured under contract by Dr Reddy's Laboratories Ltd, Hyderabad, India, following process development and scale-up of the manufacturing process from laboratory to commercial scale. The material was made to international Good Manufacturing Practice (GMP), meeting international regulatory standards, and will be suitable for use in human clinical trials.

The major value-adding milestone for Biotron, announced in January 2007, was the successful completion of the preclinical program for BIT225. This program of rigorous tests included analysing BIT225's pharmacokinetic properties, safety levels *in vivo* models, effect on respiratory, cardiovascular and neurological functions, and its potential to induce genetic abnormalities. The studies, which were performed to international standards of Good Laboratory Practice (GLP), were contracted to a leading European contract research organisation specialising in these types of studies.

The results of the preclinical studies support progression of BIT225 into human clinical trials. Submissions for regulatory and ethics approval for commencement of human trials have been made and are in the process of being assessed. The initial human trial will be a Phase I safety study in healthy volunteers, and will be followed by a proof-of-concept trial in HIV-infected patients.

BIT225 represents a novel, first in class approach to the treatment of HIV. The drug is specifically active in HIV reservoir cells and represents an opportunity to attack HIV at its source.

In addition to excellent progress with the Company's anti-HIV development program, Biotron has significantly advanced its anti-HCV program. In September 2006, the Company announced that several Biotron compounds, including the HIV lead drug BIT225, had shown good activity against *in vitro* surrogate models of HCV infections. These models include animal viruses that are closely related to HCV and which readily grow in cell cultures. HCV is unable to grow in such cultures, so industry relies on these surrogate assays to identify drugs for progression into HCV clinical development programs.

These results against HCV move the Hepatitis C program significantly closer to commencement of human trials. The preclinical data generated for BIT225 and forthcoming Phase I human safety trial will enable Biotron to initiate a proof-of-concept clinical trial of BIT225 against HCV in parallel with the proof-of-concept clinical trial against HIV-1.

In December 2006, Biotron and the ANU entered into an agreement under which existing Virion project patents and other intellectual property held by the ANU, and exclusively licensed to Biotron, were transferred to outright ownership by Biotron. In addition, Biotron received $442,703 for relinquishing rights to possible future intellectual property from certain ANU research programs which are primarily basic, non-commercial research and not relevant to Biotron's antiviral drug development programs.

Progress over the half year period demonstrates the strength of Biotron's antiviral drug portfolio, and reflects the maturing of Biotron from a research-based company to a mature drug development company with an exciting portfolio of clinical development programs.

During the half year, on-going discussions were held with potential partners regarding the Virion technology. Whilst keen to secure a partner to take the Company's compounds through into clinical development, Biotron can significantly increase the value of the technology by undertaking the proposed Phase I/IIa clinical trial before forming an alliance. This will translate into much higher returns to the Company in the form of upfront payments as well as increased milestone and royalty payments in the future.

The level of interest by the international community in Biotron's antiviral programs was reflected by the selection of Biotron to participate in a prestigious invitation-only Hepatitis C virus conference in Boston, USA in October 2006. In December 2006, Biotron scientists presented a paper of preclinical efficacy of BIT225 at the bi-annual HIV DART meeting in Cancun, Mexico. The paper received an award at the meeting, demonstrating the high level of interest in the program, and acknowledging the robustness of the science underpinning the Company's programs.

C-Test

Cancer cells have a number of characteristics that distinguish them from normal cells. Most tumour markers are neither sensitive nor specific enough to screen for cancer or to diagnose the type of cancer without the support of other clinical tests. While a number of tumour markers have been identified in the past, they have generally been found to lack sensitivity and specificity for different types of cancers.

There is a real call for new tests that allow unambiguous cancer diagnoses to be made at an early stage. The best tests will be simple and non-invasive assays that allow rapid and accurate diagnosis of the type of cancer and its early stage.

To address this need, Biotron is developing sensitive, rapid, non-invasive assays to detect and diagnose specific types of cancer. Research undertaken by the C-Test project team has led to the profiling of sera from patients with different types of cancer, showing that the glycolipid expression pattern is unique between cancer types.

The Company has developed proprietary technology for extraction and analysis of carbohydrates from blood, and has developed algorithms for analysing the expression profile of these molecules. Trials have been undertaken to demonstrate the utility of this glycomics approach for diagnosis of prostate and colorectal cancers.

In 2005 Biotron was awarded a competitive grant of $200,000 from the ACT Government to facilitate further commercial development of C-Test for these diseases. During this half year period, Biotron has continued to optimise its assay methods and identify differences in the free oligosaccharide and glycolipid expression profiles between cancer patients and normal individuals. Validation of these results is currently in progress. Additionally, work is in progress to structurally characterise specific biomarkers identified in this study.

Muscion and Other Tier 2 Projects

Muscion is a tier two project that is at an earlier stage of development compared to Virion and C-Test.

Contraction of muscle, including heart muscle, depends on release of calcium from stores inside cells through calcium channels called ryanodine receptors. The Muscion project team is identifying compounds that selectively target ryanodine receptors in heart, skeletal and insect muscle. Biotron researchers are developing drugs to boost the output of a damaged or failing heart muscle and, as part of this process, have identified peptides that stimulate heart muscle contraction *in vitro*.

During the past year, work has continued to be focused on characterisation of small molecule compounds, identified in collaboration with researchers at the ANU, which target the human ryanodine receptor. These compounds are potential therapeutics for cardiovascular disease, and are being assessed for their ability to reverse heart failure in appropriate disease models.

The remaining projects are underpinned by a platform technology, research on ion channels in membranes. These projects are at an earlier stage of development than the Virion and C-Test projects and, as such, limited resources are committed due to the Company's focus on commercial development of the Virion and C-Test projects.

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

The lead auditor's independence declaration is set out on page 5 and forms part of the Directors' Report for the half year ended 31 December 2006.

This report has been signed in accordance with a resolution of the Directors and is dated 26 February 2007:

Michael J. Hoy
Director

Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001 to the Directors of Biotron Limited

I declare that, to the best of my knowledge and belief, in relation to the review for the half year ended 31 December 2006, there have been:

(i) no contraventions of the auditor independence requirements as set out in the Corporations Act 2001 in relation to the review; and

(ii) no contraventions of any applicable code of professional conduct in relation to the review.

KPMG

S.J. Board
Partner

26 February 2007

BIOTRON LIMITED

INTERIM INCOME STATEMENT
FOR THE SIX MONTHS ENDED 31 DECEMBER 2006

	Notes	31 December 2006 $	31 December 2005 $
Gain on sale of intellectual property		402,457	-
Other operating income		-	358,056
Administration and consultants' expenses		(231,459)	(156,861)
Depreciation		(25,516)	(40,921)
Direct research and development expenses		(1,387,823)	(645,556)
Employee and director expenses		(240,785)	(288,577)
Legal fees		(68,872)	(3,103)
Rent		(22,230)	(22,295)
Travel		(37,278)	(25,739)
Refund of grant		(127,177)	-
Other expenses from ordinary activities		(97,648)	(109,430)
Operating loss before financing income		(1,836,331)	(934,426)
Finance income		94,963	46,426
Net finance income		94,963	46,426
Loss before tax		(1,741,368)	(888,000)
Income tax expense		-	-
Loss for the period	7	(1,741,368)	(888,000)
Basic loss per share attributable to ordinary equity holders	7	(1.94) cents	(1.27) cents
Diluted loss per share attributable to ordinary equity holders	7	(1.94) cents	(1.27) cents

The interim income statement is to be read in conjunction with the notes to the interim financial statements set out on pages 10 to 11.

BIOTRON LIMITED

INTERIM STATEMENT OF RECOGNISED INCOME AND EXPENSE FOR THE SIX MONTHS ENDED 31 DECEMBER 2006

	31 December 2006 $	31 December 2005 $
Income and expense recognised directly in equity	-	-
Loss for the period	(1,741,368)	(888,000)
Total recognised income and expense for the period	(1,741,368)	(888,000)

Other movements in equity arising from transactions with owners as owners are set out in note 8.

The interim statement of recognised income and expense is to be read in conjunction with the notes to the interim financial statements set out on pages 10 to 11.

BIOTRON LIMITED

INTERIM BALANCE SHEET
AS AT 31 DECEMBER 2006

	Notes	31 December 2006 $	30 June 2006 $
Current assets			
Cash and cash equivalents		2,380,443	4,623,586
Trade and other receivables		453,054	4,824
Inventories		18,265	21,538
Other		5,295	19,040
Total current assets		2,857,057	4,668,988
Non-current assets			
Property, plant and equipment		119,241	142,565
Other		2,403	2,403
Total non-current assets		121,644	144,968
Total assets		2,978,701	4,813,956
Current liabilities			
Trade and other payables		72,771	270,788
Employee entitlements		57,279	47,320
Total current liabilities		130,050	318,108
Total liabilities		130,050	318,108
Net assets		2,848,651	4,495,848
Equity			
Issued capital	8	16,865,134	16,865,134
Reserves	8	345,247	251,076
Accumulated losses	8	(14,361,730)	(12,620,362)
Total equity		2,848,651	4,495,848

The interim balance sheet is to be read in conjunction with the notes to the interim financial statements set out on pages 10 to 11.

BIOTRON LIMITED

INTERIM STATEMENT OF CASH FLOWS
FOR THE SIX MONTHS ENDED 31 DECEMBER 2006

	31 December 2006 $	31 December 2005 $
Cash flows from operating activities		
Cash receipts in the course of operations	-	393,861
Cash payments in the course of operations	(813,912)	(475,546)
Interest received	85,688	41,917
Payments for research and development	(1,512,727)	(703,656)
Net cash from operating activities	(2,240,951)	(743,424)
Cash flows from investing activities		
Payments for property, plant and equipment	(2,192)	(1,212)
Net cash from investing activities	(2,192)	(1,212)
Net decrease in cash and cash equivalents	(2,243,143)	(744,636)
Cash and cash equivalents at 1 July	4,623,586	2,112,796
Cash and cash equivalents at 31 December	2,380,443	1,368,160

The interim statement of cash flows is to be read in conjunction with the notes to the interim financial statements set out on pages 10 to 11.

.

1. REPORTING ENTITY

Biotron Limited (the 'Company') is a company domiciled in Australia.

The annual financial report of the Company as at and for the year ended 30 June 2006 is available upon request from the Company's registered office at Level 8, 261 George Street, Sydney, NSW, 2000 or at www.biotron.com.au.

2. STATEMENT OF COMPLIANCE

The interim financial report is a general purpose financial report which has been prepared in accordance with AASB 134 *Interim Financial Reports* and the Corporations Act 2001.

The Company's interim financial report does not include all of the information required for a full annual financial report, and should be read in conjunction with the 30 June 2006 annual financial report and any public announcements by the Company during the half year in accordance with continuous disclosure obligations arising under the Corporations Act 2001.

The interim financial report was authorised for issue by the Directors on 26 February 2007.

3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied by the Company in this interim financial report are the same as those applied by the Company in its financial report as at and for the year ended 30 June 2006.

4. GOING CONCERN

As at 31 December 2006, the Company had cash funds of $2,380,443. During the half year ended 31 December 2006, the Company's cash outflows were higher than normal, primarily due to additional research expenditure on preclinical development studies. The available cash funds at 31 December 2006 are sufficient to meet the Company's minimum research and operating cost commitments until at least 30 June 2008. The directors may seek to raise additional equity in the future to fund additional research above its minimum commitments.

5. ESTIMATES

The preparation of the interim financial report requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing this interim financial report, the significant judgements made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the financial report as at and for the year ended 30 June 2006.

6. FINANCIAL REPORTING BY SEGMENTS

The Company operates in the biotechnology industry in Australia.

7. LOSS PER SHARE

	31 December 2006 $	31 December 2005 $
Basic and diluted loss per share have been calculated using:		
Net loss for the six months ended 31 December	1,741,368	888,000
Weighted average number of ordinary shares	89,743,565	69,800,550

8. CAPITAL AND RESERVES

Reconciliation of movement in capital and reserves

	Share capital $	Equity remuneration reserve $	Retained losses $	Total $
Balance at 1 July 2005	12,651,368	110,850	(10,483,488)	2,278,730
Transfer from reserve to retained losses	-	(62,100)	62,100	-
Total recognised income and expense	-	-	(888,000)	(888,000)
Equity settled transactions net of tax	-	116,666	-	116,666
Balance at 31 December 2005	12,651,368	165,416	(11,309,388)	1,507,396
Balance at 1 July 2006	16,865,134	251,076	(12,620,362)	4,495,848
Total recognised income and expense	-	-	(1,741,368)	(1,741,368)
Equity settled transactions net of tax	-	94,171	-	94,171
Balance at 31 December 2006	16,865,134	345,247	(14,361,730)	2,848,651

Dividends
There were no dividends paid or declared during the six months ended 31 December 2006, or during the six months ended 31 December 2005.

Options
During the six months ended 31 December 2006:

- 1,250,000 options were issued, each exercisable at 35 cents to acquire one fully paid ordinary share at any time up to 30 September 2010.
- 250,000 options were issued, each exercisable at 40 cents to acquire one fully paid ordinary share at any time up to 30 September 2010.

These options were issued as part of the Biotron employee incentive option plan.

The fair value of the options at grant date was determined based on the Black-Scholes formula. The model inputs were the Company's share price of $0.22 at the grant date, a volatility factor of 50% based on historic share price performance and a risk free interest rate of 5.55% based on the 10 year government bond rate.

9. RELATED PARTY INFORMATION

During the six months ended 31 December 2006, Michael J. Hoy had an interest in an entity, CityPrint Holdings Pty Limited, which provided printing services to the Company. Payments to CityPrint Holdings Pty Limited, which were in the ordinary course of business and on normal terms and conditions, amounted to $25,829 (31 December 2005 – $20,704).

BIOTRON LIMITED

DIRECTORS' DECLARATION

In the opinion of the directors of Biotron Limited:

(a) the financial statements and notes, set out on pages 6 to 11, are in accordance with the Corporations Act 2001, including:

(i) giving a true and fair view of the financial position of the Company as at 31 December 2006 and of its performance, as represented by the results of its operations and cash flows for the half year ended on that date; and

(ii) complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001; and

(b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This report has been signed in accordance with a resolution of the directors and is dated 26 February 2007:

Michael J. Hoy
Director

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE MEMBERS OF BIOTRON LIMITED

We have reviewed the accompanying interim financial report of Biotron Limited, which comprises the interim balance sheet as at 31 December 2006, income statement, statement of recognised income and expense and cash flow statement for the half-year ended on that date, a statement of significant accounting policies and other explanatory notes 1 to 9 and the directors' declaration set out on pages 6 to 12.

Directors' Responsibility for the Financial Report

The directors of the Company are responsible for the preparation and fair presentation of the interim financial report in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Act 2001. This responsibility includes designing, implementing and maintaining internal control relevant to the preparation and fair presentation of the interim financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

Our responsibility is to express a conclusion on the interim financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of an Interim Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the interim financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Company's financial position as at 31 December 2006 and its performance for the half-year ended on that date; and complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001. As auditor of Biotron Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of an interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the interim financial report of Biotron Limited is not in accordance with the Corporations Act 2001, including:

a) giving a true and fair view of the Company's financial position as at 31 December 2006 and of its performance for the half year ended on that date; and:
b) complying with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the Corporations Regulations 2001.

KPMG
26 February 2007

S.J. Board
Partner

BIOTRON LIMITED

CORPORATE DIRECTORY

Directors:

Mr Michael J. Hoy (Chairman)
Dr Michelle Miller (Managing Director)
Dr Michael S. Hirshorn
Mr Bruce Hundertmark
Mr Peter G. Scott

Company Secretary:

Mr Peter J. Nightingale

Registered Office:

Level 8, 261 George Street
SYDNEY NSW 2000
Phone: 61-2 9247 8212
Fax: 61-2 9247 3932
E-mail: enquiries@biotron.com.au
Homepage: www.biotron.com.au

Research Facilities:

Innovations Building
Eggleston Road
Australian National University
CANBERRA ACT 2601
Phone: 61-2 6125 8001
Fax: 61-2 6125 8070

Share Registrar:

Computershare Investor Services Pty Limited
PO Box 523
BRISBANE QLD 4001
Phone: 61-7 3237 2100
Fax: 61-7 3229 9860

Auditors:

KPMG
Level 16, Riparian Plaza
71 Eagle Street
BRISBANE QLD 4000

Home Exchange:

Australian Stock Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

Solicitors:

Minter Ellison
88 Phillip Street
SYDNEY NSW 2000

Biotron Limited, incorporated and domiciled in Australia, is a publicly listed company limited by shares.